Launch of New Agents with Niche Roles Will Contribute to Drug Market Growth in the Treatment of Non-Muscle-Invasive Bladde

Allergan/Spectrum Pharmaceuticals’ EOquin Will Carve Out a Niche for Itself in the Immediate Postoperative Setting, According to Report from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that by 2020, the value of the market for bladder cancer therapies in the United States and Europe will have increased dramatically due in part to the arrival of emerging therapies that will carve out niche roles. The current standard of care for non-muscle-invasive bladder cancer (NMIBC) includes chemotherapy within the bladder and Bacillus Calmette-Guérin (BCG) immunotherapy, which are associated with significant side effects. Approximately 50 percent of patients either fail to respond to treatment or suffer disease recurrence within ten years.

BCG dominates the NMIBC setting, and while none of the emerging therapies will overcome BCG in treating NMIBC, they will be used as alternatives to older chemotherapies, and in the instance of Allergan/Spectrum Pharmaceuticals’ EOquin, as treatment in the immediate postoperative setting within NMIBC. According to Bladder Cancer, EOquin is expected to be the first novel agent to launch for the treatment of bladder cancer, and the only one to launch before 2015. Decision Resources forecasts that EOquin will be approved for single immediate postoperative use in 2013 in the United States and in 2014 in France, Germany, Italy, Spain and the United Kingdom. Additionally, Decision Resources forecasts approval for multiple instillations in 2017 in the United States, Germany and the United Kingdom, and in 2018 in France, Italy and Spain. In addition to EOquin, experts believe Celgene’s Abraxane will benefit NMIBC patients. Decision Resources forecasts Abraxane will launch in the United States in 2018 for bladder cancer.

“Marketers of bladder cancer therapies will find that NMIBC is the most lucrative setting because it encompasses about three-quarters of all bladder cancer patients. Within the treatment algorithm for NMIBC, the most feasible opportunity for novel therapies are the single immediate postoperative instillation and multiple adjuvant instillations for low- and intermediate-risk NMIBC,” said Analyst Mary Argent-Katwala, Ph.D. “Unlike other tumor types—such as breast cancer, colorectal cancer, lung cancer—there have been few new agents approved for bladder cancer within the last 20 years, so there are low competitive barriers to entry for bladder cancer compared with some other cancer markets.”

Webinar

On Wednesday, February 29, 2012, Decision Resources will be hosting a webinar for subscribers to the Bladder Cancer report that will highlight novel agents for the treatment of metastatic bladder cancer entitled Bladder Cancer: Novartis Poised to Dominate Market as Targeted Agents Launch for Advanced Disease. Members of the media interested in attending the webinar should contact Lisa Osgood at [email protected].

About Bladder Cancer

Bladder Cancer is offered as part of Decision Resources’ Niche Markets and Rare Diseases service. Each report assesses the commercial opportunity of a select drug market across the United States, France, Germany, Italy, Spain and the United Kingdom. The report provides detailed coverage of patient populations, current therapies, unmet needs and emerging therapies, and includes a market forecast and primary research with country-specific thought leaders.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources
Lisa Osgood, 781-993-2606
[email protected]
or
Decision Resources Group
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical  Professional Services  Consulting  Other Professional Services

MEDIA:

Logo
 Logo

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.